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HBV vaccine induces protective antibodies only in 23–56% of HIV-infected children. The
aim of our study is to evaluate the immunologic effects of a booster dose of HBV vaccine in
HIV-infected youth.
Design
53 young HIV-infected patients in whom HBV vaccination did not elicit protective Ab titers
were enrolled. All patients were on ART with optimal immunological and viral response.
Method
All patients received a booster dose of HBV vaccine (HBVAXPRO 10 μg i.m.). HBV-specific
Ab titer, viral load and CD4+ T cells were measured at baseline (T0), T1, T6 and T12
months. In a subgroup of 16 patients HBV-specific cell mediated immune responses were
evaluated at baseline, at T1 and T6.
Results
The booster dose induced seroconversion in 51% of patients at T1, 57% at T6, and49% at
T12; seroconversion rate was significantly correlated with CD4+T cells at T0 and to the CD4
nadir. The booster dose induced HBV-specific cell mediated immunity at T6 mainly in
Responders (Rs): Effector Memory CD8+T cells, HBV-specific TNFα-, IFNγ-, granzyme
secreting CD8+ T cells and IL2-secreting CD4+ T cells were significantly increased in Rs
compared to T0. In Non Responders (NRs), HBV-specific IL2-secreting CD4+ T cells, Cen-
tral and Effector Memory CD8+ T cells were the only parameters modified at T6.
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Conclusions
Seroconversion induced by a booster dose of vaccine correlates with the development of T
cell immunological memory in HIV-infected patients who did not respond to the standard
immunization. Alternate immunization schedules need to be considered in NRs.
Introduction
Chronic viral hepatitis has become a major source of comorbidity in Human Immunodefi-
ciency Virus (HIV) infected populations, with improved survival due to the success of antire-
troviral therapy (ART). A high incidence of both acute and chronic HBV infection is seen in
HIV-infected patients, probably because both viruses share the same route of transmission [1].
Notably, HIV complicates the natural course of HBV, resulting in greater levels of HBV vire-
mia, higher rate of HBV reactivation, chronic hepatitis and increased incidence of cirrhosis
and liver-related mortality [2,3].
Immune responses to vaccination, seroconversion rates and antibodies titers induced by
vaccination are known to be sub-optimal in HIV-infected people, compared with the healthy
population [4–7]. Evaluation of HBV vaccine efficacy is based on HBs antibody titers in
serum; titers above 10 IU/ml are considered protective as they are associated with protection
[8,9]. Nevertheless, it is estimated that between 4% and up to 10% of healthy individuals vacci-
nated for HBV fail to achieve protection (anti-HBs below 10 IU/ml) as they are considered
non-responders. In addition, between 13 to 60% of vaccinated healthy individuals eventually
lose their protection as anti-HBs titers tend to decrease over time, a phenomenon known as
“waning immunity” [10,11]. The clinical importance of this phenomenon is however unclear
as it has been suggested that protection may still be maintained despite declining anti-HBs Ab
titers [12].
In the settings of HIV infection, it has been shown that CD4 counts and viral load at the
time of vaccination are the main factors affecting the possibility of observing seroconversion
[13]. However, response rates to vaccination differs widely between studies, possibly because
of wide differences in the immune-virological status of the patients analyzed, the vaccine
administration route and the dosing of vaccination [14,15]. Limited data suggest that it is pos-
sible to increase HBV-vaccine response rate in healthy and HIV-infected individuals by modi-
fying vaccine dosing regimens, such as doubling the standard antigen dose.
The production of HBV-specific antibodies by B lymphocytes needs the activation of those
CD4+ T helper lymphocytes that will elicit B cell proliferation and their differentiation into
Ab-secreting plasmacells. The adjuvants included in HBV vaccines, such as alum, stimulate
the migration of dendritic cells (DCs) towards the site of injection and, after antigen capture,
their homing into the lymph nodes, where antigens will be processed and presented to CD4
+ T cells. These CD4+ T cells will trigger antibody production by secreting cytokines, thus
establishing a long-lasting immune memory [16,17]. Notably, it is conceivable that a fully
effective vaccine would elicit CTL-mediated effector mechanisms as well, as these are essential
in clearing HBV infections [18].
Current guidelines recommend a booster dose of HBV vaccine in HIV-infected patients in
whom seroconversion is not achieved but there is still controversy about the risk of viral load
rebound in HIV-infected patients, especially in pediatric populations [19].
We analyzed the immunological effects of a booster dose of HBV vaccine on HBV-specific
humoral and cell-mediate immune responses in HIV-infected young patients.
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Materials and methods
Study population
The present study is non-randomized, controlled and approved by Ethical Committee of “L.
Sacco” Hospital, Milan, Italy. Fifty-three vertically HIV-infected children, adolescents and
young adults, aged from 7 to 25 years, of both sexes, were enrolled in the study at the Pediatric
Infectious Diseases Unit at Sacco Hospital (Milan, Italy) and received a booster dose of
HBVAXPRO1 vaccine, administered by intramuscular injection into the deltoid muscle, as
approved by current CDC guidelines(19). Inclusion criteria were: non protective anti-HBs
titer (<10 IU/ml), negative anti-HBc titer, completed vaccination schedule, on ART (3 anti-
retroviral,2 classes) for at least one year, good compliance to therapy, informed consent col-
lected from parents and/or legal guardians at enrollment, as appropriate. Exclusion criteria
were: presence of comorbidities, chronic therapy with immunosuppressants and/or other
immunomodulatory drugs in the 6 months prior to study entry, blood and/or blood products
transfusions in the 3 months prior to vaccination, poor compliance to ART, protective anti
HBs titers (10 IU/ml), history of allergic reactions to a previous vaccination or hypersensitiv-
ity to a vaccine component, pregnancy and/or lactation, alcohol and/or drug abuse.
HIV-RNA and CD4+ T cells (absolute number and percentage) were assessed at baseline
(T0), after 30 ± 7 days (T1), after 6 months ± 7 days (T6) and 12 months ± 7 days (T12) after
the booster dose. Viral load was measured with the lower limit of 37 copies/ml (3.0 Quantiplex
assay; Bayer Diagnostics). At each time a clinical evaluation was performed. The study was
conducted in accordance with the ethical principles outlined in the Declaration of Helsinki
and in accordance with national and European guidelines on clinical observational studies.
Evaluation of antibody responses to HBV vaccine booster dose
For each patient, venous whole blood was collected for the dosage of anti-HBs antibodies in
the following times: at baseline (T0), T1, T6 and T12 after the booster dose. The antibodies
titers were assayed using the "Abbott system Architect anti-HBs assay", according to the proce-
dures suggested by the manufacturer.
Immunophenotypic analysis on PBMCs
A complete evaluation of HBV-specific immunological memory concerning the different func-
tional subtypes of HBV-specific circulating T cells was performed in a subgroup of 16 patients,
9 Responders (Rs) and 7 Non-responders (NRs) after the booster dose at T0, T1 and T6.
The immunophenotypic lymphocyte subpopulations were identified by flow cytometry on
previously isolated and frozen peripheral blood mononuclear cells (PBMCs). The following
CD4+ and CD8+ T cell subsets were analyzed: Naïve (CD4 +, CCR7+, CD45RA+, CD8+,
CCR7+, CD45RA+); Central Memory (CD4+, CCR7+, CD45RA-, CD8+, CCR7+, CD45RA-);
Effector Memory (CD4+, CCR7-, CD45RA-, CD8+, CCR7-, CD45RA-); Terminally Differen-
tiated (CD4+, CCR7-, CD45RA+, CD8+, CCR7-, CD45RA+). Activated memory (CD45RO
+ and CD38+) CD8+ T cells were also assessed. PBMCs were incubated for 15 minutes at
room temperature with the following monoclonal antibodies: anti-human CD4-PeCy7
(eBioscience, USA), anti-human CD8-PC5 (Beckman Coulter, California, USA), anti-human
CD38-PE (Biolegend, California, USA), anti-human CD45RO-FITC (Beckman Coulter, Cali-
fornia, USA), anti-human CD45RA-FITC (Beckman Coulter, California, USA) and anti-
human CCR7-PE (R&D Systems, Minneapolis, USA). Then, the cells were washed with phos-
phate buffered saline (PBS, Euroclone, Milan, Italy) and fixed with paraformaldehyde (PFA,
Sigma-Aldrich) 1%. The lymphocyte population was gated on the basis of its forward and side
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scatter properties, and further gated for CD4 or CD8 expression; at least 20,000 events were
acquired within the CD4 or CD8 gate. The samples were acquired using a Gallios flow cytome-
ter, and the data were analysed using Kaluza software (Beckman Coulter, California, USA).
HBV-specific cytokine production
PBMCs were cultured in RPMI 1640 medium (Euroclone, Milan, Italy) supplemented with 1%
L-glutamine (Sigma-Aldrich), 1% Penicillin/Streptomycin (Sigma-Aldrich) and 10% Human
AB Serum (Euroclone, Milan, Italy). For intracellular cytokines evaluation, PBMCs were incu-
bated for 18 hours either in absence or in presence of purified recombinant Hepatitis B Surface
Antigen (HBsAg, 1 μg/ml), adw subtype (Acris Antibodies, Germany). Anti-CD28 antibody
(R&D Systems, Minneapolis, MN, USA) was added during incubation (2 μg/mL) to facilitate
co-stimulation. During the last 6 h of stimulation, 1μg/ml of Brefeldin A (Sigma-Aldrich) was
added to block protein secretion. After 18 hours, PBMCs were incubated with monoclonal
antibodies to detect surface antigens for 15 minutes at room temperature, fixed with PFA 1%,
permeabilized with Saponin 0.5% (sigma-Aldrich) and stained with antibodies for detecting
intracellular cytokines for 45 minutes on ice. The cells were then fixed with 1% PFA. The fol-
lowing antibodies were used: anti-human CD4-PeCy5 (eBioscience, USA), anti-human
CD8-PC5 (Beckman Coulter, California, USA), anti-human IL-2-PE (eBioscience, USA), anti-
human Granzyme B-PE (R&D Systems, Minneapolis, USA), anti-human IFNγ-FITC
(eBioscience, USA), anti-human CCR7-PE (R&D Systems, Minneapolis, USA) and anti-
human TNFα-PE (Biolegend, USA). The lymphocyte population was gated on the basis of its
forward and side scatter properties, and further gated for CD4 or CD8 expression; at least
20,000 events were acquired within the CD4 or CD8 gate.. The samples were acquired using a
Gallios flow cytometer, and the data were analysed using Kaluza software (Beckman Coulter,
California, USA). Background responses from unstimulated cell cultures were not subtracted
from HBV-stimulated responses as they were uniformly low.
Statistical analysis
Descriptive statistics were reported as percentiles. Median and quartiles values were calculated
for age, CD4+ T cell counts both in absolute number and percentages at each time point. Tobit
analysis was used to estimate the relationship between the rate of seroconversion and CD4+ T
cells, both in absolute number and in percentage, at each time point. All tests were conducted
at a significance level of5%. Fractional polynomials were used to evaluate if the CD4+ rela-
tionship with seroconversion was linear. Patients were defined as Responders (R) based on the
HBsAb level>10 IU/ml at T1 after the booster dose. One Way Anova for repeated measures
with Tukey post test for multiple comparisons was used to evaluate the distribution of T-cell
subsets and functional subtypes of HBV-specific circulating T cells mean values between
responders (anti-HBs titer>10 IU/ml at T1) and non responders (anti-HBs titer <10 IU/ml at
T1) at T0, T1 and T6. All statistical analysis were performed using Stata version 14.0. (Stata
Corp, Collage Station, TX, USA) and GraphPad Prism 5.
Results
Study population characteristics
Seven patients were 7–12 years old, 15 between 13 and 18 years old, and 31 older than 18 years
old. Seroconversion rate (anti-HBs 10 IU/mL) was 51% at T1 (27 patients), 57% at T6 (30
patients), and 49% at T12 (26 patients). At each time point, all patients showed undetectable
viral load. The number of NRs was higher in older patients, as showed in Table 1.
HBV vaccine in HIV-infected individuals
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Fig 1 shows the mean values of HBs Ab titers of R and NR group at each time point. Median
and percentiles values of CD4 at each time point are shown in Table 2.
Fractional polynomials showed linearity in all relations. Tobit analysis showed the presence
of a positive relationship between CD4 nadir and the rate of seroconversion at T1 (p<0.01),
T6 (p<0.01) and T12 (p<0.05). A positive and significant relationship was found also between
CD4 counts at T0 and the rate of serocoversion at T6 (p<0.05) and T12 (p<0.05).
Naïve and memory T cells subsets
CD4+ central memory (CD45RA-, CCR7+) T cells were significantly increased at T6 in Rs
only, even though a similar trend could be observed in NRs as well, suggesting the develop-
ment of a T-cell memory after the vaccine booster dose. Major differences were observed in
CD8+ T lymphocytes. Thus, compared to baseline, central memory CD8+ T cells were
reduced at T1 and T6 in both Rs and NRs, whereas CD8+ effector memory T cells were signifi-
cantly increased at T6 in Rs only (Fig 2B). Finally, activated CD38+ CD45RO+ memory
Table 1. Stratification by age of patients with non-protective antibodies titer (HBAb<10 IU/mL, non-responder, NR) for each time of the study (T1, T6, T12).
HBsAb<10 IU/mL baseline NR T1 number (%) NR T6number (%) NR T12number (%)
7–12 years 7 2 (29%) 1 (14%) 2 (29%)
13–18 years 15 8 (53%) 6 (40%) 8 (53%)
>18 years 31 16 (52%) 16 (52%) 17 (54%)
total 53 26 (49%) 23 (43%) 27 (51%)
https://doi.org/10.1371/journal.pone.0192638.t001
Fig 1. Distribution of HBsAb titers (IU/mL) of Responders (Rs) and Non Responder (NRs) patients at T0, T1, T6
and T12. Horizontal lines indicate means.
https://doi.org/10.1371/journal.pone.0192638.g001
Table 2. Median and percentiles of CD4 count values in absolute number and percentages at T0, T1, T6, T12 and
nadir. Tobit analysis showed positive relationship between CD4 nadir (absolute number) and HbsAb seroconversion
rate at T1(p<0.01), T6 (p<0.01) and T12 (p<0.05).
P 25 P 50 P 75
CD4 T0 absolute number cell/mm3 (%) 608,5 (28,9%) 713,5 (34,5%) 910,5 (40,32%)
CD4 T1 absolute number cell/mm3 (%) 535,25 (29,35%) 750 (34,5%) 923,5 (42,82%)
CD4 T6 absolute number cell/mm3 (%) 561,5 (28,2%) 737,5 (34,75%) 878,5 (43,62%)
CD4 T12 absolute number cell/mm3 (%) 587 (28,8%) 728 (36,2%) 887 (42,87%)
Nadir CD4 absolute number cell/mm3 (%) 180 (11,6%) 306 (17,5%) 397 (26,42%)
https://doi.org/10.1371/journal.pone.0192638.t002
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Fig 2. Naïve and memory T cells subsets. (A) Gating strategy for CD4+ and CD8+ T cell subsets analysis (B) Proportion of CD4+ and
CD8+ T-cell subsets in Responder and Non Responder individuals. Immunological parameters analyzed in vaccine recipients are shown
at baseline and after the booster HBV vaccine dose (T1 and T6). Mean values and statistically significant differences are indicated. NS,
not significant. CM, central memory; EM, effector memory; TD, terminally differentiated.
https://doi.org/10.1371/journal.pone.0192638.g002
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CD8+ T cells were significantly reduced at T1 and T6 compared to baseline in responders
alone (Fig 3).
Cell-mediated immune responses (CMI)
HBV-specific IFNγ and TNFα-secreting CD8+ T cells were significantly increased at T6 com-
pared to baseline (Fig 4B) in responders alone. These data suggest that the vaccine booster
dose in responder patients correlates with the development of an effective immunological
memory and with the differentiation of CTL effector mechanisms, which are essential in clear-
ing HBV infections[18]. In contrast with these observations, an increase of HBV-specific
IL2-secreting CD4+ T cells at T1 and T6 compared to baseline was detected in both groups
(Fig 4B).
Discussion
Current guidelines recommend a 3-doses HBV vaccine regimen for children and adolescents
<19 year-old and it has been demonstrated that this regimen delivers a good response, which
is estimated to be around 90% [20–22]. However, immunization response to standard HBV
vaccine regimen drops to 28–78% in HIV-infected children and it generally fails to elicit a
strong and long-lasting immunity [21]. Studies have shown that re-vaccination or doubling
doses of vaccine are able to increase seroconversion rates in HIV-infected children, especially
in the settings of well-controlled viremia and immune recovery [23,24].
We decided to give a booster dose of HBV vaccine (HBVAXPRO 10 μg i.m.) to non-
responders HIV-infected children after standard vaccination, according to the Italian sched-
ule, in order to evaluate its efficacy in eliciting the production of protective antibodies and
CMI responses.
We observed that a booster HBV vaccine dose resulted in a seroconversion rate in 51% of
patients at T1, 57% at T6 and 49% at T12 and that it was significantly correlated with CD4+ T
lymphocyte counts at T0 and to CD4 nadir, which is in agreement with other reports
Fig 3. Percentage of CD38+CD45RO+ CD8+T cells. Activated memory CD8+ T cells analyzed in Responder and
Non-Responder HIV-infected individuals at Baseline and in response to HBV vaccine booster dose (T1 and T6).
 p<0.05, p<0.01. Mean values and SE are indicated.
https://doi.org/10.1371/journal.pone.0192638.g003
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Fig 4. Cell-mediated immune responses. (A) Gating strategy for analysis of CD4+ and CD8+ T cell cytokine secretion without stimulus or after stimulation
with HBsAg peptide(B) Percentage of HBV-specific Granzyme-, IFNγ-, and TNFα-secreting CD8+ T-cells and HBV-specific IL-2-secreting CD4+ T-cells
analyzed in Responder and Non-Responder HIV-infected individuals at baseline and in response to HBV vaccine booster dose.  p<0.05, p<0.01.
https://doi.org/10.1371/journal.pone.0192638.g004
HBV vaccine in HIV-infected individuals
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[reviewed in 22]. Responders patients showed a significant increase in CD8+ EM T cells at T1
and T6 compared to baseline, suggesting that vaccine administration was able to elicit a pro-
tective immunological recall response. This observation is in agreement with another recent
report in which a more differentiated maturation profile of CD8+ EM T cells was observed in
HBV-vaccination responders [25]. Vaccine administration did not seem to increase activation
in CD8+ memory T cells and, especially in responders, activation marker CD38 was reduced
on memory T cells both at T1 and T6 after vaccine administration. In the subgroup of patients
analyzed, responders showed marked HBV-specific cell mediated immune responses, espe-
cially at T6 compared to baseline. In particular, we observed increased CD8+ CTL effector
functions specifically in Rs with significant increases of TNFα and IFNγ secretion, suggesting
that in Rs, T cells effector functions are more potentiated than in NRs after a booster dose of
vaccine. In agreement with our data, a recent work analyzing immunological response to Hep-
atitis B vaccination in treated HIV infection, has shown that IFNγ secretion by CD8+ T cells
after Hepatitis B-specific stimulation is significantly increased in responders only [25]. Other
reports studying T-cell immunity after HBV vaccination have shown that responders to vacci-
nation display increases in cytokine production, especially Th1 cytokines, whereas non-
responders fail to mount a cytokine response when challenged with HBV antigens, which is in
agreement with our data [26–29].
Taken together these data suggest that responders patients are characterized by a more
responsive antigen-specific adaptive cell-mediated immunity, especially in the CD8+ T cell
compartment. In both groups, we observed increased HBV-specific CD4+ IL2-producing T
cells at T6 compared to baseline confirming previous observations suggesting that immuno-
logical memory provided by HBV-specific T cells may be sufficient for a recall response [30].
In addition, these data suggest that booster doses of HBV vaccine may increment the HBV-
specific immune responses, especially in individuals who have experienced waning immunity
after primary vaccine series.
In conclusion, in HIV-infected children, adolescents and young adults not responding to
the standard HBV immunization protocol or with waning immunity, seroconversion induced
by a booster dose of vaccine has been shown to be safe, as no serious side effect was reported
by the patients, and to correlate with the development of humoral and cellular immune
responses and memory.
Alternate immunization schedules should be designed and implemented for those individu-
als who do not respond even to a booster dose of vaccine.
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